296 related articles for article (PubMed ID: 23305331)
1. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
Sugimoto K; Moriyasu F; Saito K; Rognin N; Kamiyama N; Furuichi Y; Imai Y
Liver Int; 2013 Apr; 33(4):605-15. PubMed ID: 23305331
[TBL] [Abstract][Full Text] [Related]
2. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
Zocco MA; Garcovich M; Lupascu A; Di Stasio E; Roccarina D; Annicchiarico BE; Riccardi L; Ainora ME; Ponziani F; Caracciolo G; Rapaccini GL; Landolfi R; Siciliano M; Pompili M; Gasbarrini A
J Hepatol; 2013 Nov; 59(5):1014-21. PubMed ID: 23811306
[TBL] [Abstract][Full Text] [Related]
3. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
Frampas E; Lassau N; Zappa M; Vullierme MP; Koscielny S; Vilgrain V
Eur J Radiol; 2013 May; 82(5):e205-11. PubMed ID: 23273822
[TBL] [Abstract][Full Text] [Related]
4. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
[TBL] [Abstract][Full Text] [Related]
5. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
Lassau N; Koscielny S; Chami L; Chebil M; Benatsou B; Roche A; Ducreux M; Malka D; Boige V
Radiology; 2011 Jan; 258(1):291-300. PubMed ID: 20980447
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
Shiozawa K; Watanabe M; Kikuchi Y; Kudo T; Maruyama K; Sumino Y
World J Gastroenterol; 2012 Oct; 18(40):5753-8. PubMed ID: 23155317
[TBL] [Abstract][Full Text] [Related]
7. Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?
Knieling F; Waldner MJ; Goertz RS; Zopf S; Wildner D; Neurath MF; Bernatik T; Strobel D
Ultraschall Med; 2013 Feb; 34(1):38-46. PubMed ID: 23258770
[TBL] [Abstract][Full Text] [Related]
8. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
9. Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma.
Shimada M; Okawa H; Kondo Y; Maejima T; Kataoka Y; Hisamichi K; Maekawa M; Matsuura M; Jin Y; Mori M; Suzuki H; Shimosegawa T; Mano N
Tohoku J Exp Med; 2015 Nov; 237(3):173-82. PubMed ID: 26477611
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Weintraub JL; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
[TBL] [Abstract][Full Text] [Related]
11. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
Moschouris H; Malagari K; Gkoutzios P; Kalokairinou M; Stamatiou K; Chatzimichail K; Kornezos I; Karagiannis E; Kiltenis M; Papadaki MG
Med Ultrason; 2012 Jun; 14(2):87-94. PubMed ID: 22675707
[TBL] [Abstract][Full Text] [Related]
12. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
13. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
[TBL] [Abstract][Full Text] [Related]
14. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
Hoffmann K; Ganten T; Gotthardtp D; Radeleff B; Settmacher U; Kollmar O; Nadalin S; Karapanagiotou-Schenkel I; von Kalle C; Jäger D; Büchler MW; Schemmer P
BMC Cancer; 2015 May; 15():392. PubMed ID: 25957784
[TBL] [Abstract][Full Text] [Related]
15. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
Li J; Wang L; Cong N; Shi C; Bu W; Song J; Chen H
Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Chen L; Su H; Shao H; Xu K; Liang S; Liu J
Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
Nada Y; Rashad N; Eissa M; Ghonaim A; Farag K; Saadawi I; Sheha A; El Gewaity M; Abdel-Rahman O
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):99-107. PubMed ID: 29124987
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]